-
-
公开(公告)号：KR100296250B1
公开(公告)日：2001-10-25
申请号：KR1019980012818
申请日：1998-04-10
Applicant: 한국과학기술연구원
IPC: A61K36/725 , A61K36/752 , A61P3/06 , A61P9/12
Abstract: PURPOSE: A composition containing a jujube extract and a tangerine pericarp extract containing naringin and hesperidin is provided which has an effect on prevention of adult diseases and cancer such as liver diseases, hypertension, arteriosclerosis, hyperlipidemia or the like when administered to animals. CONSTITUTION: This composition comprises a jujube extract and hesperidin, hesperetin, naringin, naringenin or a mixture thereof as flavonoid originated from a tangerine pericarp extract in a weight ratio of 1:0.001 to 1:0.1. For an example, 5kg jujube is extracted with 15L water at 100deg.C for 2hr two times, followed by filtering. The filtrate is then concentrated under reduced pressure to produce 2kg extract. And 500g tangerine is extracted with 5L ethanol at 60deg.C for 5 hr to produce 190g extract. The jujube extract and tangerine pericarp extract can be orally or parenterally administered at a dose of 0.1 to 5g, preferably 0.5 to 1g and 0.1 to 10g, preferably 0.5 to 2g/kg.weight.day respectively.
-
33.发明公开네오헤스페리딘디하이드로칼콘을포함하는동맥경화증,고지혈증,간질환,고혈당증의예방및치료용조성물 失效包含NEOHESPERIDIN DIHYDROCHALCONE的组合物，用于预防和治疗高脂血症，肠梗塞，肝病和高血压
公开(公告)号：KR1020000019720A
公开(公告)日：2000-04-15
申请号：KR1019980037963
申请日：1998-09-15
Applicant: 한국과학기술연구원
Abstract: PURPOSE: A pharmaceutical composition and functional food and drink comprising neohesperid in dihydrochalcone are provided, for treating and preventing hyper lipidemia, arteriosclerosis, a liver disease and hyperglycemia. CONSTITUTION: The pharmaceutical composition comprises neohesperid in dihydrochalcone ineffective amount; and pharmaceutically acceptable carriers. The functional food or drink comprises 0.01-20 wt%, preferably 0.1-5 wt% of neohesperid in dihydrochalcone. Neohesperidin dihydrochalcone reduces the concentration of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transminase) and a lipid in blood, inhibits HMG CoA (3-hydroxy-3-methylglutaryl coenzyme) being a reduction enzyme which relates to the biosynthesis of cholesterol and ACAT (acyl CoA; cholesterol-O-acyltransferase) which transforms cholesterol into cholesteryl ester, and inhibits the damage of a liver cell and the formation of a fatty liver. Also neohesperid in dihydrochalcone strongly inhibits the macrophage-lipid complex from being deposited or adsorbed onto the intra trial surface, and reduces the concentration of blood sugar.
Abstract translation: 目的：提供一种包含二氢查耳酮中新月皮的药物组合物和功能性食品和饮料，用于治疗和预防高脂血症，动脉硬化，肝脏疾病和高血糖症。 组成：药物组合物含二氢查耳酮中的新皮肤无效量; 和药学上可接受的载体。 功能性食品或饮料包含二氢查耳酮中的新鲜皮肤的0.01-20重量％，优选0.1-5重量％。 新橙皮苷二氢查耳酮降低血清GOT（谷氨酸 - 草酰乙酸转氨酶），GPT（谷氨酸 - 丙酮酸转氨酶）和血液中的脂质的浓度，抑制与生物合成相关的还原酶的HMG CoA（3-羟基-3-甲基戊二酰辅酶） 的胆固醇和ACAT（酰基CoA;胆固醇-O-酰基转移酶），其将胆固醇转化为胆固醇酯，并且抑制肝细胞的损伤和脂肪肝的形成。 二氢查耳酮中的新生皮肤也强烈地抑制巨噬细胞 - 脂质复合物沉积或吸附到试验表面，并降低血糖浓度。
-
公开(公告)号：KR1020000019716A
公开(公告)日：2000-04-15
申请号：KR1019980037958
申请日：1998-09-15
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A61K31/34 , Y10S514/866
Abstract: PURPOSE: A pharmaceutical composition and a functional food comprising bioflavonoid compounds are provided, for descending blood sugar. CONSTITUTION: The pharmaceutical composition comprises the bioflavonoid compounds represented by the formula 1 in effective amount; and pharmaceutically acceptable carriers. In the formula 1, R¬1 represents OH, rutinosyl or rhaminosyl group, R¬2 represents H, OH or rutinosyl group, R¬3 represents H or OH group, R¬4 represents OH or method group, and X represents a single bond or a double bond. The functional food comprises 0.01-50 wt%, preferably 0.05-10 wt% of the bioflavonoid compounds. The compounds of the formula 1 descends blood sugar, and therefore can be used for treating or preventing hyperglycemia.
Abstract translation: 目的：提供包含生物类黄酮化合物的药物组合物和功能性食品，用于降血糖。 构成：药物组合物包含有效量的式1所示的生物类黄酮化合物; 和药学上可接受的载体。 在式1中，R 1表示OH，芸香酰基或脱氨基糖基，R 2表示H，OH或芸香糖基，R 3表示H或OH基，R 4表示OH或方法基，X表示单 债券或双重债券。 功能性食品包含0.01-50重量％，优选0.05-10重量％的生物类黄酮化合物。 式1的化合物降低血糖，因此可用于治疗或预防高血糖症。
-
公开(公告)号：KR100213898B1
公开(公告)日：2000-03-15
申请号：KR1019990002189
申请日：1999-01-25
Applicant: 한국과학기술연구원
IPC: A61K31/70
CPC classification number: A61K31/7048 , A23L2/52 , A23L33/105 , A61K31/352
Abstract: 본 발명은 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 함유하는 심혈관 질환 예방 및 치료제 조성물에 관한 것으로, 감귤류 과피 추출물 및 이로부터 분리 정제된 헤스페리딘 및 나린진은 HMG-CoA 환원효소의 활성을 저해하여 혈중 콜레스테롤 농도를 저하시킴으로써 심장병, 동맥경화증 등의 심혈관 질환의 예방 및 치료제로 유용하게 사용될 수 있다.
-
Patent Agency Ranking
公开(公告)号：KR1020000000751A
公开(公告)日：2000-01-15
申请号：KR1019980020559
申请日：1998-06-03
Applicant: 한국과학기술연구원
Inventor： 복성해
IPC: C12G3/04
Abstract: PURPOSE: An alcoholic beverage composition is provided to protect liver function by adding bioflavonoids, which are originally derived from citrus peel. CONSTITUTION: The alcoholic beverage composition contains 10-1000 mg of bioflavonoids per 100 ml of the alcoholic beverage wherein, the bioflavonoid is such as naringin, naringenin, hesperidin, hesperetin or mixture thereof and decreases the concentrations of serum GOT (glutamate-oxaloacetate transaminase), GPT (glutamate-pyruvate transaminase) and gamma-GTP(gamma-glutamyl transpeptidase. Bioflavonoids can be extracted from citrus or synthesized by a known method.
Abstract translation: 目的：提供一种酒精饮料组合物，通过添加最初来自柑橘皮的生物类黄酮来保护肝脏功能。 构成：酒精饮料组合物每100ml酒精饮料中含有10-1000mg生物类黄酮，其中生物类黄酮如柚皮苷，柚皮素，橙皮苷，橙皮素或其混合物，并降低血清GOT（谷氨酸 - 草酰乙酸转氨酶） ，GPT（谷氨酸 - 丙酮酸转氨酶）和γ-GTP（γ-谷氨酰转肽酶），生物类黄酮可以从柑橘中提取或通过已知方法合成。
-
-
公开(公告)号：KR1019990076178A
公开(公告)日：1999-10-15
申请号：KR1019980010888
申请日：1998-03-28
Applicant: 한국과학기술연구원
IPC: A61K31/7048 , A61P1/16
Abstract: 본 발명은 헤스페리딘(hesperidin)을 포함하는 간 질환의 예방 및 치료용 조성물에 관한 것으로, 본 발명의 조성물은 의약용 및 식품용 조성물을 포함한다. 헤스페리딘은 동물에게 투여되었을 때 혈청 GOT(glutamate-oxaloacetate transaminase), GPT(glutamate-pyruvate transaminase) 및 γGTP(γ-glutamyl transpeptidase)의 농도를 강하시키므로 본 발명의 조성물은 각종 간 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
-
公开(公告)号：KR1019990069021A
公开(公告)日：1999-09-06
申请号：KR1019980003012
申请日：1998-02-04
Applicant: 한국과학기술연구원
IPC: C12N1/20
Abstract: 본 발명은 콜레스테롤 대사억제를 필요로 하는 치료분야에서의 약물로서 이용될 수 있는 피리피로펜 에이를 생산하는 페니실린 그리세오플범의 생산균주 및 콜레스테롤대사억제제의 생산에 관한 것이다.
본 발명에 의해 안전성이 규명된 페니실리움 그리세오플범이 생산하는 피리피로펜 에이가 ACAT 저해활성을 갖고 있으므로 장내의 콜레스테롤 흡수를 저해하여 혈중콜레스테롤 농도를 저하시키는데 유효하여 고콜레스테롤증에 기인하는 고지혈증, 동맥경화 등 각종 심혈관계질환을 예방 또는 치료할 수 있는 뛰어난 효과가 있다. -
-
-
-
-
-
-
-
-
Search Results
109
records
(took 0.024 seconds)
